PUBLIC COMPANY
save$KNSAKiniksa Pharmaceuticals International, plc
$KNSA78.47-2.88%London, GBupdated 15h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase2Transition to KPL-387 Monotherapy Dosing & Administration Study
- phase3Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
- —REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
- phase2A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
- phase3Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 9, 26SELLMegna Michael R· CHIEF ACCOUNTING OFFICER−$309K↗
- Apr 9, 26SELLMoat Ross· CHIEF OPERATING OFFICER−$80K↗
- Apr 6, 26SELLPatel Sanj K· CHAIRMAN & CEO−$364K↗
- Apr 6, 26SELLQuart Barry D· −$345K↗
- Apr 6, 26SELLMoat Ross· CHIEF OPERATING OFFICER−$115K↗
- Mar 9, 26SELLRagosa Mark· CHIEF FINANCIAL OFFICER−$867K↗
- Mar 9, 26SELLRagosa Mark· CHIEF FINANCIAL OFFICER−$820K↗
- Mar 2, 26SELLPaolini John F.· CHIEF MEDICAL OFFICER−$997K↗
- Mar 2, 26SELLPaolini John F.· CHIEF MEDICAL OFFICER−$533K↗
- Mar 2, 26SELLPaolini John F.· CHIEF MEDICAL OFFICER−$262K↗
routine RSU / option mechanics (6)
- Apr 7, 26tax coverPatel Sanj K · CHAIRMAN & CEO4,831 sh
- Apr 7, 26tax coverMegna Michael R · CHIEF ACCOUNTING OFFICER1,666 sh
- Apr 7, 26tax coverRagosa Mark · CHIEF FINANCIAL OFFICER1,303 sh
- Apr 7, 26tax coverPaolini John F. · CHIEF MEDICAL OFFICER1,208 sh
- Apr 7, 26tax coverTessari Eben · CHIEF STRATEGY OFFICER846 sh
- Apr 7, 26tax coverMoat Ross · CHIEF OPERATING OFFICER774 sh
🐶 Hiring Signal
next earnings Oct 27, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that